Literature DB >> 15789648

Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin.

M G Pennisi1, M De Majo, M Masucci, D Britti, F Vitale, R Del Maso.   

Abstract

Twenty-seven dogs infected naturally with Leishmania infantum were used in a randomised controlled trial to compare the clinical and parasitological efficacy of an oral treatment with a combination of metronidazole and spiramycin (13 dogs) with the efficacy of conventional treatment with meglumine antimonate and allopurinol (14 dogs) as controls. In the test group one dog had to be withdrawn from the treatment because it developed pemphigus foliaceus; 10 of the dogs were clinically responsive but none was cured parasitologically. In the control group four dogs were withdrawn from the treatment because of side effects; eight of the dogs were clinically responsive but none was cured parasitologically. The control group showed signs of improvement after an average of 30 days, whereas the test group did not show signs of improvement until after an average of 45 days.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789648     DOI: 10.1136/vr.156.11.346

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  8 in total

1.  Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.

Authors:  M G Pennisi; S Lo Giudice; M Masucci; M De Majo; S Reale; F Vitale
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

2.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

3.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

4.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

5.  LeishVet guidelines for the practical management of canine leishmaniosis.

Authors:  Laia Solano-Gallego; Guadalupe Miró; Alek Koutinas; Luis Cardoso; Maria Grazia Pennisi; Luis Ferrer; Patrick Bourdeau; Gaetano Oliva; Gad Baneth
Journal:  Parasit Vectors       Date:  2011-05-20       Impact factor: 3.876

6.  Mathematical Modelling Using Predictive Biomarkers for the Outcome of Canine Leishmaniasis upon Chemotherapy.

Authors:  Rafaela de Sousa Gonçalves; Flaviane Alves de Pinho; Ricardo Jorge Dinis-Oliveira; Rui Azevedo; Joana Gaifem; Daniela Farias Larangeira; Eduardo Milton Ramos-Sanchez; Hiro Goto; Ricardo Silvestre; Stella Maria Barrouin-Melo
Journal:  Microorganisms       Date:  2020-05-15

7.  An immune-modulating diet increases the regulatory T cells and reduces T helper 1 inflammatory response in Leishmaniosis affected dogs treated with standard therapy.

Authors:  Laura Cortese; Mariangela Annunziatella; Anna Teresa Palatucci; Sarah Lanzilli; Valentina Rubino; Alessandro Di Cerbo; Sara Centenaro; Gianandrea Guidetti; Sergio Canello; Giuseppe Terrazzano
Journal:  BMC Vet Res       Date:  2015-12-03       Impact factor: 2.741

8.  Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease.

Authors:  Carmen Pineda; Escolastico Aguilera-Tejero; Maria C Morales; Silvia Belinchon-Lorenzo; Luis C Gomez-Nieto; Pablo Garcia; Julio M Martinez-Moreno; Maria E Rodriguez-Ortiz; Ignacio Lopez
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.